Clovis Oncology Coverage Initiated by Analysts at Piper Jaffray. (CLVS)
Equities research analysts at Piper Jaffray initiated coverage on shares of Clovis Oncology (NASDAQ: CLVS) in a research note issued to investors on Tuesday. The firm set a “neutral” rating and a $20.00 price target on the stock.
Shares of Clovis Oncology traded up 0.94% during mid-day trading on Tuesday, hitting $24.67. Clovis Oncology has a one year low of $11.19 and a one year high of $27.55. The stock’s 50-day moving average is currently $19.53.
Clovis Oncology, Inc. (Clovis) is a Development-stage Company. The Company is a Biopharmaceutical Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.